Form 4: PAVmed Inc. Insider Acquires Restricted Stock

PAVmed Inc. reports that Chief Operating Officer Shaun O'Neil was granted 110,000 shares of restricted stock on April 2, 2026, vesting in May 2029.

Summary

• Shaun O'Neil, Chief Operating Officer of PAVmed Inc., acquired 110,000 shares of common stock on April 2, 2026.
• This acquisition was in the form of restricted stock granted under the Issuer's Seventh Amended and Restated 2014 Long-Term Incentive Equity Plan.
• The restricted stock has a single vesting date of May 20, 2029, and is subject to forfeiture if the service period is not completed.
• The reported acquisition price was $0, indicating it was a grant rather than a purchase.
• Following this transaction, O'Neil beneficially owns 115,598 shares of common stock.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, indicating standard executive compensation practices and long-term alignment rather than immediate financial performance news.

Positives

• Grant of restricted stock to a key executive (COO) signals management's commitment and alignment with long-term company performance.
• The acquisition of 110,000 shares by the COO indicates confidence in the company's future prospects.
• The vesting schedule of May 20, 2029, aligns executive incentives with long-term shareholder value creation.

Negatives

• The restricted stock is subject to forfeiture, meaning the COO could lose the shares if service requirements are not met.
• The filing does not provide details on the performance conditions, if any, tied to the restricted stock grant beyond continued service.

Risks

• Risk of forfeiture of restricted stock if the reporting person does not complete the requisite service period.
• Potential for future dilution if the restricted stock vests and becomes outstanding shares.

Future Outlook

The grant of restricted stock with a vesting date in 2029 suggests a long-term outlook for the company, aligning executive incentives with sustained growth and value.

Industry Context

StockSavvy.ai notes that grants of restricted stock to senior management are a common practice in the healthcare technology sector to incentivize long-term performance and retention, aligning executive interests with those of shareholders.

Stakeholder Impact

• Shareholders: The grant aligns executive incentives with long-term shareholder value, but the potential forfeiture and future vesting could impact share count.

Next Steps

• Reporting person must complete the requisite service period to avoid forfeiture of the restricted stock.
• The restricted stock will vest on May 20, 2029, subject to completion of service.

Key Dates

Keywords

PAVmed Inc., PAVM, Form 4, Insider Transaction, Restricted Stock, Equity Grant, Executive Compensation, Securities Exchange Act, Beneficial Ownership